

Janssen-Cilag International, NV

Turnhoutseweg 30  
2340 Beerse Belgium

JCI-Office@its.jnj.com



# Memorandum

To: 68284528MMY2001 File

cc: GRAIL

From: Ivana Stracenski

Date: 12 October 2022

Re: EudraCT number 2018-000121-32

Title: A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma

## EU Clinical Trial Register

Following a very successful enrollment of patients in the United States, Janssen-Cilag International, NV, considers enrollment to be complete and does not intend to recruit more patients to this study.

Janssen confirms that no patients were enrolled in this study in EU/EEA, for this reason, no results have been published to the EudraCT system.

### Ivana Stracenski

Associate Director, EMEA Regulatory Liaison  
Oncology Therapeutic Area  
Janssen Research and Development

Janssen Pharmaceutical Companies of Johnson & Johnson  
50 – 100 Holmers Farm Way  
High Wycombe, Buckinghamshire  
HP12 4DP

**Tel:** +44 1494 65 8620 | **Mob:** +44 7786 51 1867 | **Email:** IStracen@its.jnj.com